AQR Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AQR Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-109,883	Closed	-$12.7M	–	2491
2023 Q3	$12.7M	Sell	109,883 -1,261	-1%	-$135K	0.03%	597
2023 Q2	$11.4M	Sell	111,144 -7,058	-6%	-$745K	0.02%	632
2023 Q1	$12.9M	Sell	118,202 -172,593	-59%	-$19.1M	0.03%	602
2022 Q4	$33M	Sell	290,795 -293,612	-50%	-$24.4M	0.08%	323
2022 Q3	$36.2M	Buy	584,407 +309,017	+112%	+$21.6M	0.09%	274
2022 Q2	$22M	Buy	275,390 +77,344	+39%	+$7.32M	0.05%	461
2022 Q1	$20.8M	Buy	198,046 +16,238	+9%	+$1.58M	0.04%	527
2021 Q4	$19.6M	Buy	181,808 +50,201	+38%	+$5.48M	0.04%	488
2021 Q3	$14.4M	Sell	131,607 -41,331	-24%	-$4.29M	0.03%	568
2021 Q2	$16.2M	Sell	172,938 -3,042	-2%	-$280K	0.03%	551
2021 Q1	$15.9M	Sell	175,980 -118,274	-40%	-$9.98M	0.03%	557
2020 Q4	$21.1M	Sell	294,254 -99,592	-25%	-$7.4M	0.04%	440
2020 Q3	$30.6M	Sell	393,846 -678,630	-63%	-$46.7M	0.05%	375
2020 Q2	$58.9M	Buy	1,072,476 +16,245	+2%	+$695K	0.1%	242
2020 Q1	$31.3M	Buy	1,056,231 +322,159	+44%	+$10.9M	0.05%	377
2019 Q4	$26.6M	Buy	734,072 +76,927	+12%	+$2.36M	0.03%	525
2019 Q3	$17.9M	Buy	657,145 +378,084	+135%	+$9.78M	0.02%	620
2019 Q2	$6.71M	Sell	279,061 -5,460	-2%	-$138K	0.01%	881
2019 Q1	$7.52M	Buy	284,521 +15,381	+6%	+$364K	0.01%	863
2018 Q4	$5.26M	Buy	269,140 +83,645	+45%	+$1.64M	0.01%	927
2018 Q3	$3.63M	Buy	185,495 +20,393	+12%	+$388K	﹤0.01%	1135
2018 Q2	$2.73M	Buy	165,102 +73,394	+80%	+$1.12M	﹤0.01%	1281
2018 Q1	$1.3M	Buy	91,708 +5,607	+7%	+$82.8K	﹤0.01%	1561
2017 Q4	$1.26M	Sell	86,101 -16,989	-16%	-$239K	﹤0.01%	1586
2017 Q3	$1.31M	Buy	103,090 +22,944	+29%	+$292K	﹤0.01%	1567
2017 Q2	$951K	Buy	+80,146	New	+$997K	﹤0.01%	1689
2017 Q1	–	Sell	-18,541	Closed	-$300K	–	2292
2016 Q4	$300K	Sell	18,541 -33,597	-64%	-$609K	﹤0.01%	2060
2016 Q3	$945K	Sell	52,138 -34,708	-40%	-$678K	﹤0.01%	1732
2016 Q2	$1.43M	Buy	+86,846	New	+$1.41M	﹤0.01%	1464
2015 Q4	–	Sell	-15,156	Closed	-$300K	–	2348
2015 Q3	$300K	Sell	15,156 -13,920	-48%	-$440K	﹤0.01%	1926
2015 Q2	$1.01M	Buy	+29,076	New	+$887K	﹤0.01%	1488

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AQR Capital Management's HZNP Position: Q4 2023 in Review

AQR Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 109,883 shares — an estimated $12.7M sold.

AQR Capital Management first reported a position in HZNP in Q2 2015 and held it in 31 quarters. The position peaked at $58.9M in Q2 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

AQR Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
AQR Capital Management sold 109,883 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $12.7M.
AQR Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 31 quarters.
AQR Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $58.9M in Q2 2020.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on AQR Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.